Samsung Biologics PolyPeptide Deal: A $1.8B Bet on Peptides

The Samsung Biologics PolyPeptide deal, an all-cash transaction worth approximately CHF 1.46 billion (US$1.8 billion), represents more than a conventional pharmaceutical acquisition. Samsung Biologics’ planned acquisition of Swiss peptide specialist PolyPeptide Group AG is a strategic move into one of the fastest-growing areas of pharmaceutical manufacturing: peptide-based medicines.

The transaction comes as the pharmaceutical industry undergoes a major shift toward complex therapies, particularly GLP-1 medicines used to treat obesity and diabetes. It also highlights a broader race among contract development and manufacturing organizations (CDMOs) to secure the technologies, facilities, and expertise needed to manufacture the next generation of medicines.

Samsung Biologics PolyPeptide Deal: The Key Numbers

Samsung Biologics has offered CHF 44.31 per PolyPeptide share, valuing the Swiss company at approximately CHF 1.46 billion. According to Reuters, the offer represented a premium of roughly 6.1% over PolyPeptide’s closing share price before the announcement.

Metric	Value
Acquisition value	US$1.8 billion
Offer price	CHF 44.31 per share
Minimum acceptance threshold	66.67%
Largest shareholder stake	55.65%
Transaction type	All-cash tender offer
Expected closing	Late 2026

PolyPeptide’s board unanimously recommended the offer, while its largest shareholder, Draupnir Holding AG, which owns approximately 55.65% of the company, agreed to support the transaction.

The acquisition is expected to close by the end of 2026, subject to regulatory approvals.

Why Is Samsung Interested in Peptides?

The answer largely lies in the extraordinary growth of GLP-1 medicines.

Drugs such as Novo Nordisk’s Ozempic and Wegovy, along with Eli Lilly’s Zepbound, have transformed the pharmaceutical market. Their success has created enormous demand not only for the medicines themselves, but also for the specialized manufacturing capabilities required to produce them at scale.

The numbers illustrate the opportunity:

Ozempic generated approximately US$17 billion in sales during 2025.
Wegovy sales exceeded US$11 billion.
Morgan Stanley estimates that the global obesity market could exceed US$105 billion annually by 2030.
Goldman Sachs estimates that more than 15 million Americans could eventually receive GLP-1 treatments.

Every one of these medicines depends on highly specialized pharmaceutical manufacturing.

That is precisely where PolyPeptide becomes strategically important.

What Makes PolyPeptide So Valuable?

PolyPeptide is not a household pharmaceutical brand, but it occupies a highly specialized position in the global drug supply chain.

The company develops and manufactures peptide-based active pharmaceutical ingredients (APIs), the biologically active compounds that ultimately become finished medicines.

Unlike many conventional small-molecule drugs, peptides can be challenging to manufacture because variations in production processes can affect purity, stability, safety and effectiveness.

PolyPeptide has spent decades developing expertise in peptide manufacturing, supported by a global network of facilities.

PolyPeptide’s Global Footprint

Country	Facility presence
Sweden	Manufacturing and research
Belgium	Production operations
France	Development capabilities
United States	Commercial manufacturing
India	Production support

PolyPeptide employs hundreds of scientists and engineers and has built specialized expertise that would be difficult and time-consuming for another manufacturer to replicate internally.

That makes the Samsung Biologics PolyPeptide deal about far more than acquiring factories. Samsung is gaining specialized peptide expertise, technology and a global manufacturing network.

Samsung Is Building a Multi-Modality Platform

The PolyPeptide transaction also fits into Samsung Biologics’ broader expansion strategy.

Founded in 2011, Samsung Biologics has become one of the world’s largest biologics manufacturers in just over a decade.

The company is headquartered in Songdo, South Korea, employs more than 5,300 people, reported approximately KRW 4.55 trillion in 2024 revenue, and operates five large-scale manufacturing facilities with more than 800,000 liters of total manufacturing capacity.

Its capabilities now span multiple advanced therapeutic categories, including:

Antibody-drug conjugates
mRNA therapies
Cell therapies
Gene therapies
Biosimilars
Peptide therapeutics

This diversification is central to Samsung’s multi-modality platform strategy.

Instead of concentrating on one therapeutic technology, the company is building a broader manufacturing ecosystem capable of supporting different classes of complex medicines.

The Samsung Biologics and PolyPeptide deal adds peptide manufacturing to that expanding platform.

Manufacturing Has Become the New Battleground

Drug discovery may receive most of the attention, but manufacturing can become the limiting factor when a therapy moves from laboratory development to commercial production.

Over the past decade, scientific breakthroughs have frequently moved faster than manufacturing infrastructure.

Developing a drug is one challenge. Producing millions of doses safely, consistently, and economically is another.

Industry estimates suggest that the global CDMO market could exceed US$300 billion within the next decade, as pharmaceutical companies increasingly outsource manufacturing activities.

Peptide production is particularly attractive because the potential market extends far beyond today’s obesity treatments.

Researchers are exploring peptide-based therapies for:

Alzheimer’s disease
Parkinson’s disease
Cardiovascular disorders
Infectious diseases
Cancer
Autoimmune conditions

More than 80 peptide drugs have already received regulatory approval worldwide, while hundreds more remain under development.

That means Samsung is not necessarily betting only on today’s GLP-1 boom. It is positioning itself for a broader expansion of peptide therapeutics.

Why Geography Matters

One of the most important elements of the Samsung Biologics PolyPeptide deal is its geographic dimension.

The acquisition strengthens Samsung’s manufacturing presence across Europe, North America and Asia, giving the company access to PolyPeptide’s established international network.

This geographic diversification has become increasingly valuable since the COVID-19 pandemic exposed vulnerabilities across global pharmaceutical supply chains.

Supply disruptions, export restrictions, and geopolitical tensions demonstrated the risks of concentrating critical manufacturing activities in a limited number of locations.

As a result, pharmaceutical companies increasingly value manufacturing partners that can provide capacity across multiple regions.

For Samsung, PolyPeptide offers not only specialized peptide capabilities but also a more geographically diversified manufacturing footprint.

The Competition Is Intensifying

Samsung is not alone in recognizing the potential of peptide manufacturing.

Companies active in this increasingly competitive space include:

Novo Nordisk
Eli Lilly
Lonza
CordenPharma
Thermo Fisher Scientific
WuXi Biologics

Private equity firms have also shown interest in the sector. Earlier reports indicated that investment groups including EQT and KKR had shown interest in acquiring PolyPeptide before Samsung ultimately secured the deal.

The competition reflects a larger trend across the pharmaceutical industry.

As demand for complex medicines grows, control over specialized manufacturing capacity can become a strategic advantage.

Why Investors Reacted Cautiously

Despite the strategic rationale behind the transaction, investors initially reacted cautiously to the announcement.

Samsung Biologics’ share price declined following the announcement, with concerns reportedly including:

The acquisition price
The complexity of integrating facilities across multiple countries
Increasing competition in peptide manufacturing
Potential regulatory hurdles
Uncertainty surrounding future demand for obesity treatments

The central question is whether the long-term growth of peptide therapeutics will justify Samsung’s investment.

If peptide medicines continue expanding across obesity, diabetes, oncology, cardiovascular disease and other therapeutic areas, PolyPeptide could provide Samsung with a valuable long-term manufacturing platform.

However, increasing manufacturing capacity across the industry could also intensify competition and put pressure on margins.

What the Samsung Biologics and PolyPeptide Deal Signals for Pharma

The significance of the Samsung Biologics and PolyPeptide deal extends beyond the two companies.

The pharmaceutical industry is increasingly moving toward complex therapeutic modalities.

Traditional small-molecule medicines remain important, but the industry is simultaneously expanding into monoclonal antibodies, antibody-drug conjugates, mRNA therapies, cell therapies, gene therapies and peptide-based medicines.

This shift is changing what pharmaceutical companies need from manufacturing partners.

Large-scale facilities alone are no longer enough. Companies increasingly need specialized scientific expertise, advanced technology platforms, regulatory capabilities, and geographically diversified production networks.

The acquisition therefore reflects a broader transformation in the pharmaceutical manufacturing business.

Manufacturing is becoming a strategic asset rather than simply an operational function.

The Bigger Picture

The pharmaceutical industry has repeatedly gone through periods in which new therapeutic technologies reshaped the market.

Today, peptide-based medicines are emerging as one of those transformative categories.

The success of GLP-1 treatments has accelerated investment in peptide manufacturing, but the opportunity extends well beyond obesity. As more peptide therapeutics move through clinical development, demand for specialized API manufacturing and commercial-scale production could grow alongside them.

Samsung Biologics appears to be positioning itself early.

By acquiring PolyPeptide, Samsung gains access to established peptide manufacturing capabilities, specialized expertise, and an international operational footprint.

The Samsung Biologics PolyPeptide deal may ultimately be remembered not simply as a $1.8 billion acquisition, but as a signal that the next major pharmaceutical manufacturing battle is already underway.

Sources

Author

Surbhi Ashri

Samsung Biologics PolyPeptide Deal: A $1.8B Bet on Peptides